Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Summary

A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was conducted to investigate the efficacy and safety of deferasirox in patients aged ≥ 18 years with transfusion-dependent iron overload. The objective of this extension study is to assess the long-term safety of deferasirox and to provide treatment in patients with transfusional iron overload.

Timeline

Start

2002-07

Primary completion

2003-04

Completion

2003-04

Drugs

Indications